Dr. Raghav on HER2 Amplification in Patients With CRC

Kanwal Raghav, MBBS, MD
Published: Friday, Jun 24, 2016


Kanwal Raghav, MBBS, MD, assistant professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses a study examining HER2 gene amplification in patients with metastatic colorectal cancer (mCRC).

In the study, researcher sought to identify the differences between patients with and without HER2-amplified disease, Raghav explains. Preclinical data show that HER2-amplified patients are resistant to anti-EGFR monoclonal antibodies, such as cetuximab (Erbitux) and panitumumab (Vectibix).

HER2-amplified patients who received an anti-EGFR agent plus chemotherapy did not respond to treatment, and the median progression-free survival was less than 3 months compared with 8 to 9 months in patients who were not HER2-amplified. These findings demonstrate that HER2 amplification is a negative prognostic biomarker.

Kanwal Raghav, MBBS, MD, assistant professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses a study examining HER2 gene amplification in patients with metastatic colorectal cancer (mCRC).

In the study, researcher sought to identify the differences between patients with and without HER2-amplified disease, Raghav explains. Preclinical data show that HER2-amplified patients are resistant to anti-EGFR monoclonal antibodies, such as cetuximab (Erbitux) and panitumumab (Vectibix).

HER2-amplified patients who received an anti-EGFR agent plus chemotherapy did not respond to treatment, and the median progression-free survival was less than 3 months compared with 8 to 9 months in patients who were not HER2-amplified. These findings demonstrate that HER2 amplification is a negative prognostic biomarker.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x